Waldron Private Wealth LLC Lowers Stake in Stryker Co. (NYSE:SYK)

Waldron Private Wealth LLC decreased its holdings in Stryker Co. (NYSE:SYK) by 49.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 72,495 shares of the medical technology company’s stock after selling 71,647 shares during the quarter. Stryker makes up 1.1% of Waldron Private Wealth LLC’s holdings, making the stock its 20th biggest holding. Waldron Private Wealth LLC’s holdings in Stryker were worth $26,102,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Centaurus Financial Inc. lifted its stake in Stryker by 11.3% in the 2nd quarter. Centaurus Financial Inc. now owns 1,047 shares of the medical technology company’s stock worth $356,000 after purchasing an additional 106 shares in the last quarter. Czech National Bank lifted its position in Stryker by 8.1% during the third quarter. Czech National Bank now owns 69,843 shares of the medical technology company’s stock worth $25,231,000 after buying an additional 5,235 shares in the last quarter. Unique Wealth LLC boosted its stake in Stryker by 16.0% during the third quarter. Unique Wealth LLC now owns 6,147 shares of the medical technology company’s stock worth $2,221,000 after buying an additional 848 shares during the last quarter. Farmers Trust Co. grew its holdings in Stryker by 8.6% in the 3rd quarter. Farmers Trust Co. now owns 3,369 shares of the medical technology company’s stock valued at $1,217,000 after buying an additional 267 shares in the last quarter. Finally, Canandaigua National Bank & Trust Co. raised its holdings in shares of Stryker by 0.9% during the 3rd quarter. Canandaigua National Bank & Trust Co. now owns 8,633 shares of the medical technology company’s stock worth $3,119,000 after acquiring an additional 74 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on SYK shares. Needham & Company LLC restated a “buy” rating and set a $442.00 price objective on shares of Stryker in a research report on Wednesday. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research report on Thursday. Royal Bank of Canada lifted their target price on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday. The Goldman Sachs Group boosted their price objective on shares of Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a report on Thursday. Finally, Robert W. Baird increased their target price on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $419.37.

Insiders Place Their Bets

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is currently owned by insiders.

Stryker Price Performance

SYK stock opened at $390.90 on Friday. The stock has a market cap of $149.02 billion, a price-to-earnings ratio of 50.37, a PEG ratio of 2.68 and a beta of 0.95. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The business has a 50 day moving average price of $376.56 and a 200 day moving average price of $362.38.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.86%. During the same period in the previous year, the firm earned $3.46 earnings per share. Equities research analysts anticipate that Stryker Co. will post 13.53 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were given a $0.84 dividend. This is an increase from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date was Tuesday, December 31st. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker’s dividend payout ratio is 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.